Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Chapman CH, Braunstein SE, Pouliot J, Noworolski SM, Weinberg V, Cunha A, Kurhanewicz J, Gottschalk AR, Roach MI, Hsu IC.

J Contemp Brachytherapy. 2018 Jun;10(3):193-201. doi: 10.5114/jcb.2018.76881. Epub 2018 Jun 29.

2.

Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.

Polishchuk AL, Mishra KK, Weinberg V, Daftari IK, Nguyen JM, Cole TB, Quivey JM, Phillips TL, Char DH.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):91-97. doi: 10.1016/j.ijrobp.2016.09.019. Epub 2016 Sep 23.

PMID:
27838186
3.

A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy.

Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR.

J Urol. 2017 Feb;197(2):369-375. doi: 10.1016/j.juro.2016.08.122. Epub 2016 Sep 28.

PMID:
27693447
4.
5.

Evaluation of Heart Dose for Left-Sided Breast Cancer Patients Over an 11-Year Period Spanning the Transition From 2-Dimensional to 3-Dimensional Planning.

Chang JS, Chen J, Weinberg VK, Fowble B, Sethi RA.

Clin Breast Cancer. 2016 Oct;16(5):396-401. doi: 10.1016/j.clbc.2016.05.013. Epub 2016 May 13.

PMID:
27292181
6.

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.

Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M 3rd, Gottschalk AR.

Radiat Oncol. 2016 Jan 21;11:8. doi: 10.1186/s13014-016-0585-y.

7.

Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines.

Chen CP, Johnson J, Seo Y, Weinberg VK, Shinohara K, Hsu IJ, Roach M 3rd.

Adv Radiat Oncol. 2015 Dec 17;1(1):51-58. doi: 10.1016/j.adro.2015.11.004. eCollection 2016 Jan-Mar.

8.

Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.

Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll PR, Chan JM, Paris PL.

Prostate. 2016 Mar;76(4):339-48. doi: 10.1002/pros.23125. Epub 2015 Nov 20.

9.

Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.

Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA.

J Neurooncol. 2016 Jan;126(1):193-200. doi: 10.1007/s11060-015-1959-y.

10.

Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.

Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR.

Sarcoma. 2015;2015:913565. doi: 10.1155/2015/913565. Epub 2015 Aug 9.

11.

In Reply to Kamrava and McCannel.

Mishra KK, Quivey JM, Daftari IK, Weinberg V, Castro JR, Phillips TL, Char DH.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):216-7. doi: 10.1016/j.ijrobp.2015.04.045. No abstract available.

PMID:
26279045
12.

Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes.

Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JAM, Sethi RA, Chan JK, Hsu IC.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1093-1100. doi: 10.1016/j.ijrobp.2015.04.018. Epub 2015 Jul 14.

PMID:
26194683
13.

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L.

Cancer Immunol Res. 2015 Sep;3(9):1008-16. doi: 10.1158/2326-6066.CIR-14-0227. Epub 2015 May 12.

14.

Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma.

Mishra KK, Quivey JM, Daftari IK, Weinberg V, Cole TB, Patel K, Castro JR, Phillips TL, Char DH.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):376-83. doi: 10.1016/j.ijrobp.2015.01.029. Epub 2015 Apr 1.

PMID:
25841624
15.

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.

Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ.

Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9.

PMID:
25557266
16.

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ.

Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21.

17.

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju268. doi: 10.1093/jnci/dju268. Print 2014 Nov. Erratum in: J Natl Cancer Inst. 2014 Nov;106(11):dju372 doi:10.1093/jnci/dju372.

18.

Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.

Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M 3rd.

J Contemp Brachytherapy. 2014 Jun;6(2):143-53. doi: 10.5114/jcb.2014.43248. Epub 2014 Jun 3.

19.

Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.

Polishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):839-45. doi: 10.1016/j.ijrobp.2014.04.004. Epub 2014 May 24. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):729.

PMID:
24867534
20.

A risk-adjusted definition of biochemical recurrence after radical prostatectomy.

Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):174-9. doi: 10.1038/pcan.2014.5. Epub 2014 Mar 11.

PMID:
24614692
21.

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.

Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M 3rd, Gottschalk A.

Radiat Oncol. 2014 Feb 2;9:42. doi: 10.1186/1748-717X-9-42.

22.

Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.

Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M 3rd.

Am J Clin Oncol. 2016 Apr;39(2):167-72. doi: 10.1097/COC.0000000000000032.

PMID:
24441584
23.

Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy.

Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS.

Technol Cancer Res Treat. 2015 Feb;14(1):49-60. doi: 10.7785/tcrt.2012.500394. Epub 2014 Nov 11.

PMID:
24325136
24.

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL.

Int J Cancer. 2014 May 15;134(10):2284-93. doi: 10.1002/ijc.28561. Epub 2014 Jan 2.

25.

Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence.

Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM.

Prostate. 2013 Dec;73(16):1786-95. doi: 10.1002/pros.22717. Epub 2013 Aug 29.

26.

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM.

Clin Cancer Res. 2013 Oct 15;19(20):5777-87. doi: 10.1158/1078-0432.CCR-13-0351. Epub 2013 Aug 27.

27.

Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate.

Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA.

Sci Transl Med. 2013 Aug 14;5(198):198ra108. doi: 10.1126/scitranslmed.3006070.

28.

Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.

Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL, Char DH.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):330-6. doi: 10.1016/j.ijrobp.2013.05.051. Epub 2013 Jul 23.

PMID:
23886415
29.

Palliative and oncologic co-management: symptom management for outpatients with cancer.

Bischoff K, Weinberg V, Rabow MW.

Support Care Cancer. 2013 Nov;21(11):3031-7. doi: 10.1007/s00520-013-1838-z. Epub 2013 Jun 21.

PMID:
23794100
30.

Erectile dysfunction after radiotherapy for prostate cancer: a model assessing the conflicting literature on dose-volume effects.

Rivin del Campo E, Thomas K, Weinberg V, Roach M 3rd.

Int J Impot Res. 2013 Sep;25(5):161-5. doi: 10.1038/ijir.2013.28. Epub 2013 Jun 20. Review.

PMID:
23784555
31.

A dosimetric evaluation of using a single treatment plan for multiple treatment fractions within a given applicator insertion in gynecologic brachytherapy.

Pinnaduwage DS, Cunha JA, Weinberg V, Krishnamurthy D, Nash M, Hsu IC, Pouliot J.

Brachytherapy. 2013 Sep-Oct;12(5):487-94. doi: 10.1016/j.brachy.2013.02.003. Epub 2013 Apr 11.

PMID:
23582467
32.

Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. doi: 10.1016/j.ijrobp.2013.01.027. Epub 2013 Mar 6.

PMID:
23474112
33.

The residual setup errors of different IGRT alignment procedures for head and neck IMRT and the resulting dosimetric impact.

Graff P, Kirby N, Weinberg V, Chen J, Yom SS, Lambert L, Pouliot J.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):170-6. doi: 10.1016/j.ijrobp.2012.10.040. Epub 2012 Dec 11.

PMID:
23245281
34.

Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.

Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S.

Neuro Oncol. 2013 Jan;15(1):91-6. doi: 10.1093/neuonc/nos268. Epub 2012 Oct 24.

35.

Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice.

Sahgal A, Weinberg V, Ma L, Chang E, Chao S, Muacevic A, Gorgulho A, Soltys S, Gerszten PC, Ryu S, Angelov L, Gibbs I, Wong CS, Larson DA.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):341-7. doi: 10.1016/j.ijrobp.2012.05.007. Epub 2012 Jun 17.

PMID:
22713832
36.

Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7. doi: 10.1016/j.ijrobp.2012.04.028. Epub 2012 Jun 4.

PMID:
22672747
37.

Uveal melanoma: molecular pattern, clinical features, and radiation response.

Chappell MC, Char DH, Cole TB, Harbour JW, Mishra K, Weinberg VK, Phillips TL.

Am J Ophthalmol. 2012 Aug;154(2):227-232.e2. doi: 10.1016/j.ajo.2012.02.022. Epub 2012 Apr 27.

38.

A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.

Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M 3rd, Cheung P, Sahgal A.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e657-62. doi: 10.1016/j.ijrobp.2011.09.006. Epub 2012 Jan 13.

PMID:
22245189
39.

Impact of dose hot spots on spinal cord tolerance following stereotactic body radiotherapy: a generalized biological effective dose analysis.

Sahgal A, Ma L, Fowler J, Weinberg V, Gibbs I, Gerszten PC, Ryu S, Soltys S, Chang E, Wong CS, Larson DA.

Technol Cancer Res Treat. 2012 Feb;11(1):35-40.

PMID:
22181329
40.

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Oncol Rep. 2012 Jan;27(1):3-9. doi: 10.3892/or.2011.1487. Epub 2011 Oct 4.

PMID:
21971890
41.

Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.

Chen CP, Weinberg VK, Jahan TM, Jablons DM, Yom SS.

J Thorac Oncol. 2011 Nov;6(11):1857-64. doi: 10.1097/JTO.0b013e318229a41e.

42.

Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.

Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M 3rd, Hsu IC.

Brachytherapy. 2012 Sep-Oct;11(5):348-53. doi: 10.1016/j.brachy.2011.07.009. Epub 2011 Sep 21.

PMID:
21937284
43.

Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation.

Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM.

PLoS One. 2011;6(9):e24004. doi: 10.1371/journal.pone.0024004. Epub 2011 Sep 1.

44.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.

45.

A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer.

Chung HT, Noworolski SM, Kurhanewicz J, Weinberg V, Roach Iii M.

BJU Int. 2011 Oct;108(8 Pt 2):E164-70. doi: 10.1111/j.1464-410X.2010.10061.x. Epub 2011 Mar 24.

46.

Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.

Krishnamurthy D, Weinberg V, Cunha JA, Hsu IC, Pouliot J.

Brachytherapy. 2011 Nov-Dec;10(6):461-5. doi: 10.1016/j.brachy.2011.01.012. Epub 2011 Mar 11.

PMID:
21397569
47.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

48.

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34. doi: 10.1016/j.ijrobp.2010.10.026. Epub 2010 Dec 22.

PMID:
21183287
49.

High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes.

Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7. doi: 10.1016/j.ijrobp.2010.09.021. Epub 2010 Dec 14.

PMID:
21163586
50.

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.

Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR.

Cancer Causes Control. 2011 Jan;22(1):141-50. doi: 10.1007/s10552-010-9684-5. Epub 2010 Nov 20.

Supplemental Content

Loading ...
Support Center